A candesartan cilexetil pharmaceutical composition with high bioequivalence and preparation method thereof

By optimizing the composition and granulation process of candesartan cilexetil, micro-flakes with a particle size of 10-30 micrometers were prepared, solving the problem of use in children and patients with dysphagia, and achieving bioequivalence and commercial applicability with the original formulation.

CN118490651BActive Publication Date: 2024-11-15HQ PHARMA (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410969213.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-15
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

Existing candesartan cilexetil drug compositions are not suitable for use in children and patients with dysphagia, and have not achieved bioequivalence with the original formulation.

Method used

Using a specific ratio of candesartan cilexetil, corn starch, lactose, hydroxypropyl cellulose, polyethylene glycol 6000, calcium carboxymethyl cellulose, and magnesium stearate as ingredients, and through optimized granulation process, micro-flakes with a particle size of 10-30 micrometers are prepared to ensure good in vitro dissolution profiles and bioequivalence.

Benefits of technology

It achieves easy swallowing, accurate dosage, and flexible adjustment, making it suitable for children and patients with swallowing difficulties. It is also bioequivalent to the original formulation and suitable for commercial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a candesartan cilexetil pharmaceutical composition with high bioequivalence and a preparation method thereof, belonging to the technical field of pharmaceutical compositions. The candesartan cilexetil pharmaceutical composition comprises, by weight percentage: candesartan cilexetil 1.5-3%; filler 70-85%; binder 2-4%; stabilizer 1-6%; disintegrant 3-5% and lubricant 0.1-1%; the particle size of the candesartan cilexetil is 10-25 microns. In order to ensure that the dissolution and dissolution behavior of candesartan cilexetil tablets are similar to those of the original research, and to ensure the continuity of the process, the present invention selects polyethylene glycol 6000 as a stabilizer, which can not only play a solubilizing effect, but also can meet the bioequivalence with the control preparation under the premise of ensuring stable product quality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical compositions, and in particular relates to a candesartan cilexetil pharmaceutical composition with high bioequivalence and a preparation method thereof. Background Art

[0002] Essential hypertension is caused by a combination of genetic and environmental factors. It is a progressive cardiovascular syndrome caused by many causes, which can lead to changes in heart and blood vessel function and structure. Therefore, the main goal of essential hypertension treatment is to minimize the overall risk of cardiovascular death and disability.

[0003] The overall prevalence of hypertension in children is 2%-5%, and the main type is essential hypertension, especially during adolescence. As in adults, the main risk factors for essential hypertension in children are excessive obesity and unhealthy lifestyles. Environmental, low birth weight and genetic factors may also be important. Children with hypertension are very likely to continue to suffer from hypertension in adulthood and are very likely to develop target organ damage, especially left ventricular hypertrophy and vascular sclerosis. Childhood hypertension is associated with cardiovascular events in adulthood. Therefore, clinical recommendations are to adopt healthier dietary patterns and increase physical activity to reduce the prevalence of essential hypertension. Children who have been diagnosed with hypertension should be managed according to evidence-based treatment guidelines.

[0004] Candesartan Cilexetil is a prodrug suitable for the treatment of essential hypertension. Candesartan Cilexetil was developed by Takeda Pharmaceutical Co., Ltd. of Japan under the trade name Atacand. In 2002, the candesartan cilexetil tablets "Bilos" produced by Takeda Pharmaceutical Co., Ltd. of Japan were approved for import. At present, the domestically marketed tablets have not been approved for use in pediatric patients. Therefore, it is necessary to develop a drug that is suitable for children and has pediatric indications with greater socioeconomic effects. Mini-tablets (Mini-tablets, referred to as micro-tablets) are usually less than 3mm in diameter and are multi-unit preparations. They have the advantages of easy swallowing, accurate dosage and flexible dosage adjustment, and can be used for children, patients with dysphagia, etc.

[0005] Patent CN117442577A discloses a candesartan cilexetil microtablet and a preparation method and application thereof, wherein the candesartan cilexetil microtablet is composed of an active ingredient, a filler, a binder, a disintegrant, a stabilizer, and a lubricant. The candesartan cilexetil microtablet is obtained by tableting. By optimizing the granulation process, especially the timing of adding the active ingredient and lactose, and adding a stabilizer, candesartan cilexetil microtablets with good content uniformity and good stability can be prepared on the basis of ensuring that the product quality of the candesartan cilexetil microtablets is consistent with that of the original candesartan cilexetil tablets, and the candesartan cilexetil microtablets have good medication compliance, are suitable for children and patients with dysphagia, and are suitable for commercial production, but the invention does not verify the efficacy of the microtablets.

[0006] Patent CN116492336A discloses a candesartan cilexetil pharmaceutical composition, which contains candesartan cilexetil, octanoic acid decanoic acid macrogol glyceride, propylene glycol, lactose, microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose calcium, and magnesium stearate, wherein the D90 of candesartan cilexetil is 25-50 μm, and the mass ratio of candesartan cilexetil, octanoic acid decanoic acid macrogol glyceride and propylene glycol is 1:(1.25-2):(1-1.5). The invention draws on the design concept of self-emulsification and microemulsion and improves it, adding emulsifiers and co-emulsifiers to the solid preparation components to improve the solubility of the raw material and the absorption of the drug, but the candesartan cilexetil pharmaceutical composition does not involve that the microtablets are not suitable for children.

[0007] Patent CN110917170A discloses a capsule preparation containing candesartan cilexetil and a preparation method thereof, wherein 2-32 parts of candesartan cilexetil, 110-150 parts of diluent, 210-150 parts of diluent, 0.5-8 parts of disintegrant, 1-10 parts of binder, and 0.5-10 parts of low melting point oily compound are mixed by weight and prepared into micro-pellets by extrusion spheronization, 0.05-4 parts of lubricant are added to the micro-pellets for mixing, and the mixture is filled into a capsule shell to prepare a capsule preparation. The capsule preparation containing candesartan cilexetil of the invention adopts the preparation process of extrusion spheronization, has high solubility, and greatly improves the bioavailability of candesartan cilexetil compared with the commercially available candesartan cilexetil preparation; the capsule preparation prepared by the invention is also not suitable for children.

[0008] Therefore, it is necessary to develop a candesartan cilexetil pharmaceutical composition that is easy to swallow, has accurate dosage and flexible dosage adjustment, is suitable for children, patients with dysphagia, etc., and can achieve bioequivalence with the original research. Summary of the invention

[0009] Based on the deficiencies in the prior art, the present invention aims to provide a candesartan cilexetil pharmaceutical composition that is easy to swallow, has accurate dosage and can flexibly adjust the dosage, is suitable for children, patients with dysphagia, etc., and can achieve bioequivalence with the original "Bilos".

[0010] In order to achieve the above object, the present invention adopts the following technical solution:

[0011] A candesartan cilexetil pharmaceutical composition with high bioequivalence, comprising, by weight percentage: 1.5-3% candesartan cilexetil; 70-85% filler; 2-4% binder; 3-6% stabilizer; 3-5% disintegrant and 0.1-1% lubricant;

[0012] in,

[0013] The particle size of the candesartan cilexetil is 10-30 microns;

[0014] The filler is a mixture of corn starch and lactose; the mass ratio of the two is 1:2.5-6; preferably, the mass ratio of the corn starch to lactose is 1:4-5.

[0015] The binder is hydroxypropyl cellulose;

[0016] The stabilizer is polyethylene glycol 6000;

[0017] The disintegrant is carboxymethylcellulose calcium;

[0018] The lubricant is magnesium stearate.

[0019] As a preferred embodiment, the candesartan cilexetil pharmaceutical composition comprises, by weight percentage: 2% candesartan cilexetil; 15.2% corn starch; 68% lactose; 5% hydroxypropyl cellulose; 5.4% polyethylene glycol 6000; 4.0% carboxymethyl cellulose calcium and 0.4% magnesium stearate.

[0020] The present invention also provides a method for preparing the candesartan cilexetil pharmaceutical composition, comprising the following steps:

[0021] (1) Dissolve the prescribed amount of polyethylene glycol 6000 in purified water and stir until completely dissolved to obtain solution 1 for later use;

[0022] (2) Dissolve the hydroxypropyl cellulose in water and stir until completely dissolved to obtain solution 2; mix candesartan cilexetil and 5-15 times the amount of lactose in the API prescription and add them to solution 2; set the homogenizer speed to 3000 rpm and homogenize for 10 minutes and pass through an 80-mesh sieve to obtain a suspension;

[0023] (3) placing corn starch and remaining lactose in a fluidized bed, spraying solution 1 and the suspension in sequence, and drying and granulating after spraying to obtain granules;

[0024] (4) The granules obtained in step (3) are mixed with carboxymethylcellulose calcium and then with magnesium stearate, and finally tabletted to obtain candesartan cilexetil microtablets.

[0025] The mass fraction of polyethylene glycol 6000 in the solution 1 in the above step (1) is 6-10%;

[0026] The mass fraction of hydroxypropyl cellulose in the suspension described in step (2) is 2-6%;

[0027] The parameters of the fluidized bed described in the above step (3) are: inlet air temperature 45-65°C; material temperature 25-40°C; inlet air volume 15-35Hz; outlet air temperature 30-40°C; atomization pressure 0.10-0.20mpa; and liquid supply speed 10-30rpm.

[0028] The drying in the above step (3) is completed when the drying reaches LOD ≤ 2%;

[0029] The sieve particle size of the granules in step (3) above is 0.8-2.0 mm;

[0030] The rotation speed of mixing with carboxymethylcellulose calcium and magnesium stearate in the above step (4) is 15 rpm, and the mixing time is 15 minutes.

[0031] The candesartan cilexetil microtablets have a tablet weight of 25 mg and a hardness of 15-40N.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] (1) The present invention controls the excipients and production conditions, and under the premise of ensuring low production cost and simple and easy preparation process, through appropriate prescription composition and preparation process, candesartan cilexetil has a good in vitro dissolution curve, product quality and bioequivalence.

[0034] (2) Candesartan cilexetil belongs to BCS class II and is very slightly soluble in solutions with a pH range of 1.1 to 8.9. The particle size of the raw material has a significant influence on the solubility of the product. In order to ensure that the solubility and dissolution behavior of candesartan cilexetil tablets are similar to those of the original research and to ensure the continuity of the process, the present invention selects polyethylene glycol 6000 as a stabilizer, which not only has the effect of solubilizing, but also can meet the bioequivalence with the control preparation while ensuring the stability of product quality, and is suitable for commercial production. DETAILED DESCRIPTION

[0035] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0036] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.

[0037] The present invention is further described below by way of specific examples. Unless otherwise specified, the various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels.

[0038] Example 1-3 A candesartan cilexetil pharmaceutical composition with high bioequivalence and a preparation method thereof

[0039] The prescription is as follows:

[0040]

[0041] The preparation method comprises the following steps:

[0042] Weigh all raw and auxiliary materials except carboxymethylcellulose calcium and magnesium stearate according to the prescription amount.

[0043] Adhesive preparation: ① 8% PEG6000 solution: slowly add PEG6000 into the purified water under stirring, and stir until dissolved. ② 5% HPC suspension containing API and lactose: slowly add HPC into the purified water under stirring, and stir until dissolved. Slowly add the mixed API and 10 times lactose mixture under high-speed stirring, set the homogenizer speed to 3000rpm, homogenize for 10 minutes, and pass through an 80-mesh sieve.

[0044] Granulation: First spray the PEG6000 solution and then spray the suspension containing API and lactose. The parameters are as follows: inlet air temperature 50°C, material temperature 30°C, inlet air volume 25Hz, outlet air temperature 35°C, atomization pressure 0.15mpa, liquid supply speed 20rpm. Drying: Drying is terminated when LOD≤2%.

[0045] Use a 1.5 mm sieve to sieve the particles.

[0046] Weigh the whole particles and calculate the amount of carboxymethylcellulose calcium and magnesium stearate required. ① Carboxymethylcellulose calcium: add it to the mixer with the materials at 15 rpm for 15 minutes; ② Magnesium stearate: continue to add magnesium stearate to the mixer at 15 rpm and mix for 5 minutes.

[0047] The tablet weight is 25 mg, the tablet weight difference is maintained within ±7.5%, the tablet surface is smooth, and the hardness is 15-40N.

[0048] Example 4 A candesartan cilexetil pharmaceutical composition with high bioequivalence and its preparation method

[0049] The prescription is as follows: The difference from Example 3 is that the particle size of the raw material is different.

[0050]

[0051] The preparation method is the same as that of Example 1-3.

[0052] Performance testing:

[0053] 1. Dissolution performance test

[0054] Based on the dissolution behavior of the preparations prepared in Examples 1-4 and the control preparation (purchased from Takeda Pharmaceutical Company Limited, batch number 12289319) in a highly discriminating pH 4.0 acetate buffer, the dissolution behavior of the products was evaluated using a similarity factor f2. The results are shown in Table 1 below.

[0055] Table 1

[0056]

[0057] Conclusion: Under the same API particle size, increasing the amount of PEG can accelerate the dissolution rate of the preparation, indicating that PEG can increase the solubility and dissolution rate of the API; the dissolution rate of the preparation significantly decreases when the particle size increases.

[0058] 2. Stability test

[0059] Detection method: Place at high temperature of 50℃ for 30 days and test the relevant substances. The specific test results are shown in Table 2 below.

[0060] Table 2

[0061]

[0062] Conclusion: The stability of the preparation was good within the range of PEG dosage of 1.4-5.4%.

[0063] 3. Bioequivalence study

[0064] The test results are shown in Table 3 below.

[0065] Table 3

[0066]

[0067] Conclusion: The results of the bioequivalence test show that the Cmax of Example 2 is 123.99%, and the geometric mean ratio of the 90% confidence interval is within 80%-125%, and the geometric mean ratio of AUC0-t and AUC0-∞ is within 80%-125%. The geometric mean ratio of Cmax, AUC0-t, and AUC0-∞ of Examples 1 and 4 is within 80%-125%. It is bioequivalent to the original research. Therefore, the amount of PEG in the self-made preparation is in the range of 1.4-5.4%, but the 5.4% amount of PEG will result in a higher Cmax, and the subsequent prescription dosage needs to be reduced, and the particle size of the raw material needs to be controlled within the range of 10-25μm.

[0068] Comparative Example 1

[0069] The difference from Example 2 is that the preparation method is different. Specifically, the method disclosed in the prior art CN117442577A is used for pilot scale-up, with a batch size of 600,000 pieces. The pilot micro-pieces are tested for content uniformity; the results are as follows:

[0070]

[0071] The preparation of micro-tablets in patent CN117442577A was mainly carried out in the laboratory, and a batch expansion test (600,000 tablets) was subsequently carried out on this basis. The content uniformity results were poor, indicating that this process is not suitable for commercial production.

[0072] Comparative Example 2

[0073] The difference from Example 2 is that the particle size of the API is different, specifically: the particle size of the API is 28 μm.

[0074] Candesartan cilexetil drug micro-tablets were prepared according to the method of Example 2, and their solubility was tested.

[0075] Detection method: Dissolution test was carried out in pH 6.5 phosphate + 0.35% Tween medium. The specific test results are shown in Table 4 below.

[0076] Table 4

[0077]

[0078] From the dissolution results in the above table, it can be seen that as the particle size of the API increases, the dissolution becomes slower. When the particle size of the API D90 = 28 μm, the dissolution behavior of Comparative Example 2 is not similar to that of the control preparation.

[0079] Comparative Example 3

[0080] The difference from Example 2 is that no polyethylene glycol 6000 is added; the prescription is as follows:

[0081]

[0082] Candesartan cilexetil drug micro-tablets were prepared according to the method of Example 2, and their stability was tested.

[0083] Detection method: Place at a high temperature of 50°C for 30 days and test the relevant substances. The specific test results are shown in Table 5 below.

[0084] Table 5

[0085]

[0086] According to the test data in Table 5 above, after being placed at a high temperature of 50°C for 30 days, the microchips prepared in Example 2 have good stability, while the impurities in the microchips prepared in Comparative Example 3 grow rapidly and there is a risk of exceeding the limit, which poses a greater risk to product stability and quality during storage.

[0087] The above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, a person skilled in the art can still modify or make equivalent substitutions to the specific implementation schemes of the present invention. Any modifications or equivalent substitutions that do not depart from the spirit and scope of the present invention are within the scope of protection of the claims of the present invention.

Claims

1. A candesartan cilexetil pharmaceutical composition with high bioequivalence, Features: The composition includes, by weight percentage: 2% candesartan cilexetil; 15.2% corn starch; 73.6% lactose; 3% hydroxypropyl cellulose; 1.4% polyethylene glycol 6000; 4.4% carboxymethyl cellulose calcium; 0.4% magnesium stearate; the particle size D90 of the candesartan cilexetil is controlled to be 10 microns; The preparation method of the candesartan cilexetil pharmaceutical composition comprises the following steps: (1) Dissolve the prescribed amount of polyethylene glycol 6000 in purified water and stir until completely dissolved to obtain solution 1 for later use; (2) Dissolve the hydroxypropyl cellulose in water and stir until completely dissolved to obtain solution 2; mix candesartan cilexetil and 10 times the amount of lactose in the prescription amount of candesartan cilexetil and add them to solution 2, set the homogenizer speed to 3000 rpm, homogenize for 10 minutes, and pass through an 80-mesh sieve to obtain a suspension; (3) placing corn starch and remaining lactose in a fluidized bed, spraying solution 1 and the suspension in sequence, and drying and granulating after spraying to obtain granules; (4) mixing the granules obtained in step (3) with carboxymethylcellulose calcium and then with magnesium stearate, and finally tableting to obtain candesartan cilexetil microtablets; The mass fraction of polyethylene glycol 6000 in the solution 1 described in step (1) is 8%; the mass fraction of hydroxypropyl cellulose in the suspension described in step (2) is 5%; The parameters of the fluidized bed in step (3) are: inlet air temperature 50°C, material temperature 30°C, inlet air volume 25Hz, outlet air temperature 35°C, atomization pressure 0.15mpa, and liquid supply speed 20rpm; The drying in step (3) is completed when the LOD is less than or equal to 2%. The sieve particle size of the granules is 1.5 mm. The candesartan cilexetil microtablets obtained in step (4) have a tablet weight of 25 mg and a hardness of 15-40N.

2. A candesartan cilexetil pharmaceutical composition with high bioequivalence, Features: The composition includes, by weight percentage: 2% candesartan cilexetil; 15.2% corn starch; 68% lactose; 5% hydroxypropyl cellulose; 5.4% polyethylene glycol 6000; 4.0% carboxymethyl cellulose calcium; 0.4% magnesium stearate; the particle size D90 of the candesartan cilexetil is controlled to be 10 microns; The preparation method of the candesartan cilexetil pharmaceutical composition comprises the following steps: (1) Dissolve the prescribed amount of polyethylene glycol 6000 in purified water and stir until completely dissolved to obtain solution 1 for later use; (2) Dissolve the hydroxypropyl cellulose in water and stir until completely dissolved to obtain solution 2; mix candesartan cilexetil and 10 times the amount of lactose in the prescription amount of candesartan cilexetil and add them to solution 2, set the homogenizer speed to 3000 rpm, homogenize for 10 minutes, and pass through an 80-mesh sieve to obtain a suspension; (3) placing corn starch and remaining lactose in a fluidized bed, spraying solution 1 and the suspension in sequence, and drying and granulating after spraying to obtain granules; (4) mixing the granules obtained in step (3) with carboxymethylcellulose calcium and then with magnesium stearate, and finally tableting to obtain candesartan cilexetil microtablets; The mass fraction of polyethylene glycol 6000 in the solution 1 described in step (1) is 8%; the mass fraction of hydroxypropyl cellulose in the suspension described in step (2) is 5%; The parameters of the fluidized bed in step (3) are: inlet air temperature 50°C, material temperature 30°C, inlet air volume 25Hz, outlet air temperature 35°C, atomization pressure 0.15mpa, and liquid supply speed 20rpm; The drying in step (3) is completed when the LOD is less than or equal to 2%. The sieve particle size of the granules is 1.5 mm. The candesartan cilexetil microtablets obtained in step (4) have a tablet weight of 25 mg and a hardness of 15-40N.